Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Clovis Oncology Inc (CLVS), Sarepta Therapeutics Inc (SRPT): Three Healthcare Stocks to Keep an Eye On

Page 1 of 2

The healthcare industry is slowly becoming what the pre-crash technology industry was of the early 2000’s. The emergence of new technologies in medicine, an aging working population, and retiring baby boomers are all expected to provide tremendous growth to the industry over the next several decades.

Many companies will inevitably capitalize on this growth, creating excellent investing opportunities for investors. For the next 20 years, nearly 10,000 people will turn 65 everyday — a rate never seen in history, and by 2050, the number of people over the age of 60 will increase by nearly 300%, according to the US Census Bureau. The following healthcare stocks are positioned to take advantage of this change in demographics and are showing promising signs of growth in both, the near and short-term.

Clovis Oncology Inc (NASDAQ:CLVS)

Hitting gold

On June 3, Clovis Oncology Inc (NASDAQ:CLVS)‘s stock doubled after the announcement that it’s cancer drug, rucaparib, blew Phase I expectations out of the water. The experimental drug that treats ovarian cancer showed a clinical benefit in 89% of its users, and is targeted towards patients who have resistance towards current disease treatments. Currently, there are no options available to treat this mutation, making rucaparib a potential cash cow for Clovis Oncology Inc (NASDAQ:CLVS). Because of the results, Clovis Oncology Inc (NASDAQ:CLVS) wants to start Phase II trials in the next couple of months.

Clovis Oncology Inc (NASDAQ:CLVS) recently announced a plan to offer $170 million in common stock in an effort to pay for more drug development programs and other general corporate purposes. Clovis Oncology Inc (NASDAQ:CLVS) is in the process of developing many other anti-cancer drugs, most of which are already contracted out to national pharmaceutical companies.

Breaking through

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is the proud owner of the world’s most expensive drug, Solaris. At nearly $410,000 per year for treatment, this remedy that treats paroxysmal nocturnal hemoglobinuria (“PNH”), a chronic disease which destroys red blood cells and causes anemia, is certainly not cheap. However, from an investor’s perspective, this stock is very appetizing.

The FDA has given the Solaris drug “fast-track status;” a label that the FDA gives to potential break-through drugs. Over the last five years, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has also proved to be one of the fastest growing healthcare stocks. Its EPS alone has grown at 87.72% on average annually during the past five years.

Keep a keen eye on the status of the Solaris drug in the near future. If all goes as expected, this health care stock could shoot to the moon.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!